argenx Balance Sheet Health
Financial Health criteria checks 4/6
argenx has a total shareholder equity of $4.3B and total debt of $34.0M, which brings its debt-to-equity ratio to 0.8%. Its total assets and total liabilities are $4.8B and $534.3M respectively.
Key information
0.8%
Debt to equity ratio
US$33.96m
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.10b |
| Equity | US$4.26b |
| Total liabilities | US$534.31m |
| Total assets | US$4.80b |
Recent financial health updates
No updates
Recent updates
argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)
Jan 23Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat
Oct 31argenx: Myositis Data Could Add Billions In Value
Sep 25Argenx: Strong Setup For Outperformance In 2025
Jun 28argenx: Innovation Over Losses In Autoimmune Arena
May 07argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Feb 01Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod
Sep 21Argenx's neuromuscular disorder drug Vyvgart wins approval in EU
Aug 11Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M
Jul 28argenx: A Very Good Start For Vyvgart
May 25argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
May 18argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
Mar 07argenx: Vyvgart's Approval A Key Step For Continued Value Creation
Dec 22argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Nov 30argenx: R&D Day Goes Unnoticed
Aug 23argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
Jun 30Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals
Jun 07Argenx raises ~$1B in global offering
Feb 03argenx to raise $750M in proposed global offering
Feb 01argenx on target to file efgartigimod applications in Japan and Europe
Jan 08argenx and Zai Lab collaborate for Efgartigimod in Greater China
Jan 06Argenx inks $98M deal to secure accelared review status for efgartigimod
Nov 23argenx (ARGX) Investor Presentation - Slideshow
Nov 18Financial Position Analysis
Short Term Liabilities: ARGX's short term assets ($4.3B) exceed its short term liabilities ($499.6M).
Long Term Liabilities: ARGX's short term assets ($4.3B) exceed its long term liabilities ($34.7M).
Debt to Equity History and Analysis
Debt Level: ARGX has more cash than its total debt.
Reducing Debt: ARGX's debt to equity ratio has increased from 0.7% to 0.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARGX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ARGX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/27 05:12 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
argenx SE is covered by 49 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Charles Pitman-King | Barclays |
| Richard Parkes | BNP Paribas Exane |